Clinical trial · Observational
A Multi-omics Study of Epithelial Ovarian Cancer
A Multi-omics Study on the Invasiveness of Epithelial Ovarian Cancer
NCT03742856CI-TRIAL-00035801unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to analyze the multi-omics results between epithelial ovarian cancer (EOC) patient with different FIGO stages and pathological subtypes. The multi-omics profiles include whole exome sequencing, analysis of transcriptomics and metabolomics. A comprehensive multi-omics will reveal the invasiveness and tumorigenesis of EOC.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epithelial Ovarian Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
| Metabolomics | — | UNRESOLVED | — |
| Transcriptomics | — | UNRESOLVED | — |
| Tumorigenesis | — | UNRESOLVED | — |
| Tumor Invasiveness | — | UNRESOLVED | — |
| Whole Exome Sequencing | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| A multi-omics analysis | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Frequencies of somatic driving mutations
- timeFrame
- Two years
- description
- The differences of frequencies of somatic driving mutations will be compared between patients of different FIGO stages and different pathological subtypes.
Secondary outcomes (3)
- measure
- Frequencies of alteration of RNA expression
- timeFrame
- Two years
- description
- The alteration of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between patients of different FIGO stages and different pathological subtypes.
- measure
- Frequencies of alteration of protein expression and signal pathway
- timeFrame
- Two years
- description
- The alteration of patterns of protein expression and signal pathway will be compared between patients of different FIGO stages and different pathological subtypes.
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Confirmed primary epithelial ovarian cancer * Signed an approved informed consents * Feasible for biopsy Exclusion Criteria: * Not meeting all of the inclusion criteria
References
Publications (0)
Data not yet available
No reference posted for this study.